Hydantoin derivative compounds, pharmace utical compositions, and methods of using same
AssigneeGPI NIL Holdindgs, Inc.
InventorGregory S. Hamilton
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to novel hydantoin derivative compounds, pharmaceutical compositions containing such compounds, and methods for their use in preventing and/or treating neurological disorders, including physically damaged nerves and neurodegenerative diseases; for treating alopecia and promoting hair growth; for treating vision disorders and/or improving vision; for treating memory impairment and/or enhancing memory performance; and for treating sensorineural hearing loss by administering such compounds.
Claims62
A compound of the formula:
- 14
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or a C1-C8 alkyl or alkenyl;
- R is selected from the group consisting of hydrogen, phenyl, biphenyl, cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclooctyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, benzofuranyl, thiophenyl, imidazolyl, oxazolyl, benzoxazolyl, benzoxazinyl, thiazolyl, isoxazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, benzopyranyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, phenazinyl, phenothiazinyl, phenoxazinyl, and adamantyl;
- wherein R may be optionally substituted with one substituent which is selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof;
- wherein when R is hydrogen, D is a C5-C7 alkyl or C5-C8 alkenyl;
- wherein when R is phenyl and D is a bond, R must be substituted with phenyl, hydroxyl, trifluoromethyl, C2-C6 straight or branched chain alkyl or alkenyl, C3-C4 alkoxy or C2-C4 alkenyloxy, phenoxy, or benzyloxy;
- wherein when R is 4-trifluoromethylphenyl, both X substituents must be O.
A pharmaceutical composition comprising an effective amount of a compound and a pharmaceutically acceptable carrier, wherein the compound is of the formula:
- 15
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method of treating a neurological disorder in an animal, comprising:
- administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound is of the formula:
- 16
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method of stimulating growth of damaged peripheral nerves, comprising:
- administering to damaged peripheral nerves an effective amount of a compound to stimulate or promote growth of the damaged peripheral nerves, wherein the compound is of the formula:
- 17
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method for promoting neuronal regeneration and growth in animals, comprising:
- administering to an animal an effective amount of a compound to promote neuronal regeneration, wherein the compound is of the formula:
- 18
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method for preventing neurodegeneration in an animal, comprising:
- administering to an animal an effective amount of a compound to prevent neurodegeneration, wherein the compound is of the formula:
- 19
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A compound of the formula:
- 20
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or a C1-C8 alkyl or alkenyl;
- R is selected from the group consisting of hydrogen, phenyl, biphenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1,2,3,4-tetrahydronaphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinolizinyl, furyl, thiophenyl, imidazolyl, oxazolyl, benzopyranyl, thiazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and adamantyl;
- wherein R may be optionally substituted with one substituent which is selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof;
- wherein when R is hydrogen, D is a C5-C8 alkyl or alkenyl;
- wherein when R is phenyl and D is a bond, R must be substituted with C2-C3 or C1-C6 straight or branched chain alkyl or alkenyl, C3-C4 alkoxy or C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, or amino.
A pharmaceutical composition comprising an effective amount of a compound and a pharmaceutically acceptable carrier, wherein the compound is of the formula:
- 21
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method of treating a neurological disorder in an animal, comprising:
- administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound is of the formula:
- 22
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method of stimulating growth of damaged peripheral nerves, comprising:
- administering to damaged peripheral nerves an effective amount of a compound to stimulate or promote growth of the damaged peripheral nerves, wherein the compound is of the formula:
- 23
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method for promoting neuronal regeneration and growth in animals, comprising:
- administering to an animal an effective amount of a compound to promote neuronal regeneration, wherein the compound is of the formula:
- 24
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8 alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
A method for preventing neurodegeneration in an animal, comprising:
- administering to an animal an effective amount of a compound to prevent neurodegeneration, wherein the compound is of the formula:
- 25
- where
- each X independently is O, S, or NR2;
- R2 is selected from the group consisting of cyano, nitro, hydrogen, C1-C4 alkyl, hydroxy, and C1-C4 alkoxy;
- D is a direct bond or C1-C8, alkyl or alkenyl;
- R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring;
- wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;
- or a pharmaceutically acceptable salt, ester, or solvate thereof.
Dependencies are inferred from the claim text.